|
1
|
Haggar FA and Boushey RP: Colorectal
cancer epidemiology: Incidence, mortality, survival, and risk
factors. Clin Colon Rectal Surg. 22:191–197. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cidon EU, Alonso P and Masters B: Markers
of response to antiangiogenic therapies in colorectal cancer: Where
are we now and what should be next? Clin Med Insights Oncol. 10
Suppl 1:S41–S55. 2016. View Article : Google Scholar
|
|
3
|
Figueredo A, Rumble RB, Maroun J, Earle
CC, Cummings B, McLeod R, Zuraw L and Zwaal C; Gastrointestinal
Cancer Disease Site Group of Cancer Care Ontario's Program in
Evidence-based Care, : Follow-up of patients with curatively
resected colorectal cancer: A practice guideline. BMC Cancer.
3:262003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zetter BR: Angiogenesis and tumor
metastasis. Annu Rev Med. 49:407–424. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kumar P, Wang JM and Bernabeu C: CD 105
and angiogenesis. J Pathol. 178:363–366. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Romani AA, Borghetti AF, Del Rio P,
Sianesi M and Soliani P: The risk of developing metastatic disease
in colorectal cancer is related to CD105-positive vessel count. J
Surg Oncol. 93:446–455. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Weidner N, Semple JP, Welch WR and Folkman
J: Tumor angiogenesis and metastasis-correlation in invasive breast
carcinoma. N Engl J Med. 324:1–8. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kumar S, Ghellal A, Li C, Byrne G, Haboubi
N, Wang JM and Bundred N: Breast carcinoma: Vascular density
determined using CD105 antibody correlates with tumor prognosis.
Cancer Res. 59:856–861. 1999.PubMed/NCBI
|
|
9
|
Akagi K, Ikeda Y, Sumiyoshi Y, Kimura Y,
Kinoshita J, Miyazaki M and Abe T: Estimation of angiogenesis with
anti-CD105 immunostaining in the process of colorectal cancer
development. Surgery. 131 Suppl 1:S109–S113. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Goldis DS, Sferdian MF, Tarţă C, Fulger
LO, Totolici BD and Neamţu C: Comparative analysis of microvessel
density quantified through the immunohistochemistry expression of
CD34 and CD105 in rectal cancer. Rom J Morphol Embryol. 56:419–424.
2015.PubMed/NCBI
|
|
11
|
Ottaviano G, Cappellesso R, Mylonakis I,
Lionello M, Favaretto N, Giacomelli L, Spoladore C, Marchese-Ragona
R, Marino F, Staffieri A, et al: Endoglin (CD105) expression in
sinonasal polyposis. Eur Arch Otorhinolaryngol. 272:3367–3373.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hamilton SR: Carcinoma of the colon and
rectumWHO Classification of Tumours of the Digestive System. Bosman
FT, Carneiro F, Hruban RH and Theise ND: IARC Press; Lyon: pp.
134–146. 2010
|
|
13
|
Watanabe T, Itabashi M, Shimada Y, Tanaka
S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, et
al: Japanese Society for Cancer of the Colon and Rectum (JSCCR)
guidelines 2010 for the treatment of colorectal cancer. Int J Clin
Oncol. 17:1–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Miyachi H, Kudo SE, Ichimasa K, Hisayuki
T, Oikawa H, Matsudaira S, Kouyama Y, Kimura YJ, Misawa M, Mori Y,
et al: Management of T1 colorectal cancers after endoscopic
treatment based on the risk stratification of lymph node
metastasis. J Gastroenterol Hepatol. 31:1126–1132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bosari S, Lee AK, DeLellis RA, Wiley BD,
Heatley GJ and Silverman ML: Microvessel quantitation and prognosis
in invasive breast carcinoma. Hum Pathol. 23:755–761. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vermeulen PB, Gasparini G, Fox SB,
Colpaert C, Marson LP, Gion M, Beliën JA, de Waal RM, van Marck E,
Magnani E, et al: Second international consensus on the methodology
and criteria of evaluation of angiogenesis quantification in solid
human tumours. Eur J Cancer. 38:1564–1579. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Saad RS, Liu YL, Nathan G, Celebrezze J,
Medich D and Silverman JF: Endoglin (CD105) and vascular
endothelial growth factor as prognostic markers in colorectal
cancer. Mod Pathol. 17:197–203. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Seon BK, Takahashi N, Haba A, Matsuno F,
Haruta Y, She XW, Harada N and Tsai H: Angiogenesis and metastasis
marker of human tumors. Rinsho Byori. 49:1005–1013. 2001.PubMed/NCBI
|
|
19
|
Li C, Gardy R, Seon BK, Duff SE, Abdalla
S, Renehan A, O'Dwyer ST, Haboubi N and Kumar S: Both high
intratumoral microvessel density determined using CD105 antibody
and elevated plasma levels of CD105 in colorectal cancer patients
correlate with poor prognosis. Br J Cancer. 88:1424–1431. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nassiri F, Cusimano MD, Scheithauer BW,
Rotondo F, Fazio A, Yousef GM, Syro LV, Kovacs K and Lloyd RV:
Endoglin (CD105): A review of its role in angiogenesis and tumor
diagnosis, progression and therapy. Anticancer Res. 31:2283–2290.
2011.PubMed/NCBI
|
|
21
|
Sica G, Lama G, Anile C, Geloso MC, La
Torre G, de Bonis P, Maira G, Lauriola L, Jhanwar-Uniyal M and
Mangiola A: Assessment of angiogenesis by CD105 and nestin
expression in peritumor tissue of glioblastoma. Int J Oncol.
38:41–49. 2011.PubMed/NCBI
|
|
22
|
Park S, Sorenson CM and Sheibani N:
PECAM-1 isoforms, eNOS and endoglin axis in regulation of
angiogenesis. Clin Sci (Lond). 129:217–234. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tabata M, Kondo M, Haruta Y and Seon BK:
Antiangiogenic radioimmunotherapy of human solid tumors in SCID
mice using (125)I-labeled anti-endoglin monoclonal antibodies. Int
J Cancer. 82:737–742. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tanaka F, Otake Y, Yanagihara K, Kawano Y,
Miyahara R, Li M, Yamada T, Hanaoka N, Inui K and Wada H:
Evaluation of angiogenesis in non-small cell lung cancer:
Comparison between anti-CD34 antibody and anti-CD105 antibody. Clin
Cancer Res. 7:3410–3415. 2001.PubMed/NCBI
|
|
25
|
Yao Y, Pan Y, Chen J, Sun X, Qiu Y and
Ding Y: Endoglin (CD105) expression in angiogenesis of primary
hepatocellular carcinomas: Analysis using tissue microarrays and
comparisons with CD34 and VEGF. Ann Clin Lab Sci. 37:39–48.
2007.PubMed/NCBI
|
|
26
|
Yao Y, Kubota T, Takeuchi H and Sato K:
Prognostic significance of microvessel density determined by an
anti-CD105/endoglin monoclonal antibody in astrocytic tumors:
Comparison with an anti-CD31 monoclonal antibody. Neuropathology.
25:201–206. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Allegra CJ, Yothers G, O'Connell MJ,
Sharif S, Petrelli NJ, Colangelo LH, Atkins JN, Seay TE,
Fehrenbacher L, Goldberg RM, et al: Phase III trial assessing
bevacizumab in stages II and III carcinoma of the colon: Results of
NSABP protocol C-08. J Clin Oncol. 29:11–16. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Goel S, Duda DG, Xu L, Munn LL, Boucher Y,
Fukumura D and Jain RK: Normalization of the vasculature for
treatment of cancer and other diseases. Physiol Rev. 91:1071–1121.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hurwitz H, Fehrenbacher L, Novotny W,
Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S,
Holmgren E, et al: Bevacizumab plus irinotecan, fluorouracil, and
leucovorin for metastatic colorectal cancer. N Engl J Med.
350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Saltz LB, Clarke S, Díaz-Rubio E,
Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS,
Rivera F, et al: Bevacizumab in combination with oxaliplatin-based
chemotherapy as first-line therapy in metastatic colorectal cancer:
A randomized phase III study. J Clin Oncol. 26:2013–2019. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tebbutt NC, Wilson K, Gebski VJ, Cummins
MM, Zannino D, van Hazel GA, Robinson B, Broad A, Ganju V, Ackland
SP, et al: Capecitabine, bevacizumab, and mitomycin in first-line
treatment of metastatic colorectal cancer: Results of the
Australasian Gastrointestinal Trials Group Randomized Phase III MAX
Study. J Clin Oncol. 28:3191–3198. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kobayashi H, Mochizuki H, Ishiguro M and
Sugihara K: Risk factor for distant metastasis from colorectal
cancer and surveillance. Frontier in Colorectal Cancer. 4:264–268.
2008.(In Japanese).
|
|
33
|
Wang Y, Gong C, Yang L, Wu Q, Shi S, Shi
H, Qian Z and Wei Y: 5-FU-hydrogel inhibits colorectal peritoneal
carcinomatosis and tumor growth in mice. BMC Cancer. 10:4022010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Folkman J: Seminars in Medicine of the
Beth Israel Hospital, Boston. Clinical applications of research on
angiogenesis. N Engl J Med. 333:1757–1763. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Folkman J: Fighting cancer by attacking
its blood supply. Sci Am. 275:150–154. 1996. View Article : Google Scholar : PubMed/NCBI
|
